BARNES-JEWISH HOSPITAL
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
About Us
News & Events
Maps & Locations
Contact Us
Google Search
PATIENT AND VISITOR INFORMATION
TREATMENT PROGRAMS
PREVENTION AND SCREENING
RESEARCH
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Home
Treatment Programs
Types of Cancer
Clinical Trial Search Results
Share
Lung Cancer
NCI Information
Our Treatment Approach
Clinical Trials
Support Groups
Effects of Treatment
Assess Your Risk
Patient Stories
Podcasts
Treatment Team
NEW SEARCH
RETURN TO SEARCH RESULTS
Number:
201103353
Principal Investigator:
Waqar, Saiama
Title:
A Randomized Double Blind Phase III efficacy & safety study of PF-00299804 vs.erlotinib for the treatment of Advanced NSCLC following progression after, of intollerance to, at least one prior chemotherapy
Phase:
III
Disease Site:
Lung
Participating Site(s):
Main Campus
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
Contact:
800-600-3606 or
info@ccadmin.wustl.edu
Description:
The purpose of this research study is to compare the good and bad effects of an investigational drug called dacomitinib with erlotinib, a drug that is already approved and is commonly used to treat patients with advanced non-small cell lung cancer (NSCLC) who have had at least one prior chemotherapy regimen.
More Information:
(Links will take you off this web site)
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)